US Circuit split on use of prescribing data: Supreme Court review next?
This article was originally published in Scrip
A three-judge panel of the US Court of Appeals for the Second Circuit struck down a Vermont law restricting aggregators from selling their information about physicians' prescribing patterns to drug manufacturers, saying it unconstitutionally restricts commercial speech. The law was challenged by three healthcare research firms – IMS Health, the analytics firm SDI, Wolters Kluwer Health – and the PhRMA trade group (whose members use the data), which argued that the Vermont law – which banned the use of prescriber data for marketing unless the doctor consented - would hurt public access to healthcare information and violated commercial speech.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.